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Short Communication
The response of leptin, interleukin-6 and fat oxidation to feeding
in weight-losing patients with pancreatic cancer
MD Barber1, DC McMillan*,2, AM Wallace3, JA Ross1, T Preston4 and KCH Fearon1
1University Department of Surgery, Royal Inf irmary, Edinburgh EH3 9YW, UK; 2University Department of Surgery, Royal Inf irmary, Glasgow G31 2ER, UK;
3Department of Clinical Biochemistry, Royal Inf irmary, Glasgow G31 2ER, UK; 4Isotope Biochemistry Laboratory, Scottish Universities Environmental
Research Centre, East Kilbride, Glasgow G75 OQF, UK
At baseline, weight-losing pancreatic cancer patients (n¼ 7) had lower leptin (Po0.05) but higher cortisol, interleukin-6, resting
energy expenditure and fat oxidation than healthy subjects (n¼ 6, Po0.05). Over a 4 h feeding period, the areas under the curve for
glucose, cortisol and interleukin-6 were greater (Po0.05), but less for leptin in the cancer group (Po0.05). Therefore, it would
appear that low leptin concentrations, increased fat oxidation and insulin resistance are associated with increased concentrations of
cortisol and interleukin-6 in weight-losing patients with pancreatic cancer.
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The discovery of leptin, an adipocyte-secreted protein that acts on
the central nervous system to regulate body weight in animals
(Pelleymounter et al, 1995), has stimulated interest in the role of
leptin in humans both in the obese and cachectic states. Evidence,
in animals, suggests that circulating leptin concentrations regulate
energy intake centrally (primarily through appetite) and expendi-
ture (primarily through substrate oxidation) by a control feedback
loop involving neuropeptide Y (Inui, 1999). Evidence, in humans,
indicates that the major role of leptin appears in the adaptation to
reduced energy intake and reduced body fat stores (Havel, 2002).
In studies of cachectic cancer patients, the role of leptin appears
more complex since the fall in leptin concentrations which
accompanies a loss of body fat appears not to be associated with
an improvement in energy balance (Simons et al, 1997; Wallace
et al, 1998). Little is known about the regulation of leptin
production during feeding and its effect on fat oxidation in
humans. However, recent studies have indicated that increased
leptin concentrations are associated with increased fat oxidation
(Havel, 2002).
It is now recognised that the presence of a systemic
inflammatory response is associated with an increase in substrate
oxidation and resting energy expenditure in patients with chronic
disease states such as cancer (Fearon et al, 1999; Kotler, 2000). In
particular, the pro-inflammatory cytokine interleukin-6 is likely to
be important in this catabolic process since it is known to act on
the central nervous system to reduce appetite (Havel, 2002), results
in increased substrate oxidation when infused (Stouthard et al,
1995) and is recognised to be associated with weight loss in cancer
patients (Fearon et al, 1991; Scott et al, 1996).
It is of interest that interleukin-6 shares structural and some
functional similarities to leptin. Both are released in response to
injury at a similar time (Wallace et al, 2000), and are capable of
activating the same hypothalamic receptor (Inui, 1999), and
therefore interleukin-6 might mimic the anorexogenic effect of
leptin. This concept is consistent with the observations that
intracerebroventricular infusion of physiological doses of inter-
leukin-6 in rodents has been shown to result in reduction of fat
mass without inducing an acute-phase protein response (Walle-
nius et al, 2002).
It has long been recognised that following an overnight fast,
provision of calories will reduce fat oxidation in both healthy
subjects and weight-losing cancer patients (Selberg et al, 1990).
Such an intervention would allow critical examination of the inter-
relationships between circulating concentrations of leptin, inter-
leukin-6 and fat oxidation during feeding in healthy subjects and
weight-losing cancer patients.
PATIENTS AND METHODS
Weight-losing cancer patients with an unequivocal diagnosis of
pancreatic cancer were studied. No patient had clinical evidence of
ascites, peripheral oedema, diabetes mellitus or malabsorption nor
had undergone surgery, chemotherapy or radiotherapy in the
preceding 4 weeks. No patient had clinical or radiological evidence
of infection, were jaundiced or severely anaemic or were receiving
steroids.
Healthy weight-stable subjects were studied as a control group.
Study design
The study protocol was as previously described (Barber et al,
2000). Briefly, after an overnight fast, at 08:00 h baseline blood
samples were collected for assessment of leptin, interleukin-6,
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insulin and cortisol. Following a rest period of at least 20 min
baseline, oxygen consumption and carbon dioxide production
were measured over a 20 min period using a ventilated hood
indirect calorimeter (Deltatrac II, Datex, Helsinki, Finland).
Resting energy expenditure was calculated as previously described
(Barber et al, 2000). Healthy subjects and cancer patients received
hourly meals (for 4 h) of a balanced whole protein liquid
nutritional supplement (Fortisip, Nutricia, Zoetermeer, Holland),
each meal providing one-twelfth of the estimated energy require-
ment (measured resting energy expenditure X 1.44). During the 4 h
feeding period, the subject or patient continued to rest in the
supine position and energy expenditure measurements were
repeated every 40 min for 20 min and blood sampling was repeated
every 30 min.
Urine was collected by healthy subjects and cancer patients for
the 24 h period prior to attendance. The urine was collected over
the 4 h study period to provide an estimate of urinary nitrogen
excretion in the fed state.
The study was approved by the Research Ethics Committee of
Edinburgh Royal Infirmary University NHS trust. All subjects were
informed of the purpose and procedure of the study and gave
written consent.
Methods
Serum leptin was measured using a commercial kit (Human Leptin
RIA kit; Linco Research Inc., St Charles, MO, USA). The limit of
sensitivity was 0.5mg l1, and the intra- and inter-assay coefficients
of variation were 5.8 and 6.5%, respectively, over the sample
concentration range.
Circulating concentrations of interleukin-6 were measured using
a solid-phase sandwich enzyme-linked immunosorbent assay
(ELISA, Diaclone Research, Bescanon, France). The lower level of
detection was 2 mg l1 and the intra- and inter-assay variabilities
were less than 4 and 6%, respectively, over the sample concentra-
tion range.
Circulating concentrations of insulin and cortisol were mea-
sured as previously described (Fearon et al, 1998).
Total body water was measured using a bioelectrical impedance
system (Xitron 4000B; Xitron Technologies, San Diego, CA, USA).
The error of the method is approximately 10% (Hannan et al,
1995). Body fat was calculated using the following formulae:
Fat-free mass (kg)¼ total body water/0.73
Body fat mass¼weightfat-free mass
Urinary nitrogen was estimated using a rapid combustion and
thermal conductivity cell method (Leco FP-328, St Joseph, MI,
USA).
Energy expenditure was measured by indirect calorimetry using
a ventilated hood system (Deltatrac II, Datex, Helsinki, Finland).
Coefficient of variation was less than 5%. Substrate utilisation was
calculated from oxygen consumption and carbon dioxide produc-
tion (provided by indirect calorimetry) and urinary N excretion in
the fasting (baseline) and fed (after 200 min of the feeding
protocol) states, as previously described (Barber et al, 2000).
Statistics
Data are presented as the median and range. Where appropriate,
serial data from time points during the feeding period were tested
for statistical significance using the Friedman Rank test. Analysis
between control and cancer groups was performed using the
Mann– Whitney U-test. Statistical analysis was performed using
SPSS software (SPSS Inc., Chicago, IL, USA).
RESULTS
The characteristics of healthy subjects and patients are shown in
Table 1. At baseline, compared with the healthy subjects, cancer
patients had less weight and fat mass (Po0.05) and had lower
circulating concentrations of leptin (Po0.05), but higher concen-
trations of cortisol and interleukin-6 (Po0.05). Resting energy
expenditure and fat oxidation were greater in the cancer group
(Po0.05).
Over the 4 h feeding period, insulin concentrations increased
significantly both in the control (P¼ 0.006) and cancer groups
(Po0.001). In contrast, glucose concentrations remained stable in
the control (P¼ 0.318) and cancer groups (P¼ 0.101). Cortisol
concentrations fell significantly both in the control (Po0.001) and
cancer groups (Po0.001). Leptin concentrations remained stable
in the control (P¼ 0.186) and cancer (P¼ 0.062) groups. Similarly,
in the cancer group with detectable interleukin-6 concentrations,
they were not significantly altered (P¼ 0.869) over the feeding
period. Energy expenditure increased in the control (P¼ 0.002)
and cancer groups (P¼ 0.003). In contrast, fat oxidation only fell
in the cancer group (P¼ 0.008).
The areas under the curve for the measured parameters are
given in Table 2. Over the feeding period, the area under the curve
for glucose, cortisol and interleukin-6 were greater in the cancer
group compared with the control group (Po0.05), whereas leptin
was significantly less for the cancer group (Po0.05). The areas
under the curve for insulin, energy expenditure and fat oxidation
were similar in both groups.
Table 1 Baseline characteristics of healthy subjects and weight losing cancer patients
Healthy subjects (n¼ 6) Cancer patients (n¼ 7)
Median (range) Median (range) P-value
Sex (m/f) 3/3 3/4 1.000
Age (years) 54 (50–62) 59 (56–75) 0.018
BMI 26.3 (20.8–36.1) 20.4 (16.4–22.9) 0.010
Body fat mass (kg) 26.3 (16.8–40.3) 16.0 (12.6–20.1) 0.015
Weight loss (%) 15.9 (12.7–20.7)
Insulin (mIU l1) 6.2 (4.5–16.8) 4.2 (3.5–8.1) 0.063
Glucose (mmol l1) 5.1 (4.5–5.6) 5.6 (4.4–6.1) 0.564
Cortisol (nmol l1) 521 (382–626) 639 (437–677) 0.022
Leptin (mg l1) 12.9 (5.1–49.8) 2.1 (1.3–14.6) 0.032
Interleukin-6 (ng l1) o2 (o2–o2) 4.1 (o2–9.4) 0.024
Resting energy expenditure (kcal day1) 1565 (1270–1940) 1425 (1035–1710) 0.199
Resting energy expenditure (kcal (kg body weight)1 day1) 20.2 (16.3–23.3) 24.3 (19.5–27.7) 0.046
Fat oxidation (mg min1) 64.4 (39.4–83.0) 71.1 (20.4–109.3) 0.474
Fat oxidation (mg (kg body fat mass)1 min1) 2.44 (1.48–3.14) 4.73 (1.19–6.85) 0.032
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The molar ratio (molecular weights of leptin and interleukin-6
are 16 and 26 kDa, respectively) of the areas under the curve for
leptin and interleukin-6 was approximately 1000-fold greater in the
weight-losing cancer group (Po0.01).
DISCUSSION
Few studies have examined the acute effect of feeding on
circulating leptin concentrations in healthy subjects. Clapham
et al (1997) reported no change in leptin concentrations in either
adipose tissue or the plasma for 3 h following a mixed meal.
Similarly, Dallongeville et al (1998) reported no change up until 6 h
following a mixed meal. The results of the present study confirm
these findings and would indicate that, in healthy subjects,
circulating leptin concentrations are not altered acutely on feeding.
To our knowledge, there have been no studies which have
examined the acute effect of feeding in cancer patients.
In the present study, at baseline, weight-losing cancer patients
had less fat, lower leptin concentrations and had increased
concentrations of the catabolic mediators cortisol and interleu-
kin-6. Despite a lower body weight and body fat mass, the cancer
group had a higher resting energy expenditure and higher fat
oxidation compared with the control group. Over the feeding
period, the total amount of circulating leptin was less and the total
amounts of glucose, cortisol and interleukin-6 were greater than
that of the control group. Taken together, the results of the present
small study would suggest that weight loss in pancreatic cancer
patients is associated with an increase in catabolic mediators,
insulin resistance and a reduction in leptin concentrations.
The clinical consequences of lower circulating concentrations of
leptin and the greater concentrations of glucose, cortisol and
interleukin-6 in cancer patients in the fed state are likely to be
profound. These include continuing loss of lean and adipose tissue
and the consequent decline in physical function (Fearon et al,
1999) and continuing impairment of the immune system and the
consequent increase in infection (Fantuzzi and Faggioni, 2000).
Given their similar receptor activity, the reciprocal relationship
between interleukin-6 and leptin is of interest. Indeed, between the
control and cancer groups, there was a large increase in their molar
ratio. Whether this is responsible for or secondary to the insulin
resistance seen in the present study is not clear. However, an
infusion of interleukin-6 has been shown to increase cortisol
concentrations and fat oxidation in cancer patients (Stouthard
et al, 1995). Furthermore, euglycaemic hyperinsulinaemic glucose-
clamp studies have reported that insulin resistance increases with
elevated circulating concentrations of interleukin-6 (Makino et al,
1998). These results would be consistent with observations that
pancreatic tumour cell lines produce increased amounts of
interleukin-6 (Wigmore et al, 2002).
If this were to be the case, then reduction of interleukin-6
concentrations would be a prerequisite for the reduction of insulin
resistance and fat oxidation in weight-losing pancreatic cancer
patients. Therefore, it is of interest that administration of fish oil
has been shown to decrease interleukin-6 and cortisol concentra-
tions and preserve fat tissue in these patients (Barber, 2001).
In summary, low circulating concentrations of leptin, increased
fat oxidation and insulin resistance are associated with increased
circulating concentrations of cortisol and interleukin-6 in weight-
losing patients with pancreatic cancer.
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